Most Recent
Kicking off its appeal of a finding that it couldn't walk away from a $672 million merger agreement with Mayne Pharma, US drug company Cosette has told a court that Mayne was not upfront about its financial position prior to the deal.
US drug maker Cosette is appealing a judge’s decision not to disqualify himself from Mayne Pharma's lawsuit seeking damages over the termination of their $672 million if he is appointed to case manage the dispute.
It ditched a planned $627 million union, now US drug maker Cosette must pay more than $13 million toward Mayne Pharma's costs of the legal fallout. Whether it owes the "substantial damages" Mayne is claiming is an issue for another day.
Mayne Pharma cannot access invoices from Cosette’s solicitors at Corrs Chambers Westgarth, with a judge saying he was not hopeful that they would help to resolve a costs fight related to litigation over their collapsed $672 million merger.
Lender White Oak may argue that settlement communications in proceedings over the collapse of supply chain finance company Greensill were in furtherance of fraud and should be turned over, after partially succeeding in a privilege fight with insurers BCC Trade Credit and Tokio Marine.
Australia's richest person Gina Rinehart could be on the hook for millions of dollars in royalty payments, in a long-running battle over lucrative iron ore mining tenements in Western Australia's Pilbara region.
Construction PRO
Mining magnate Gina Rinehart is on the hook for royalties payable to the heirs of iron ore pioneers Don Rhodes and Peter Wright, a judge has held in a long-running battle over lucrative tenements in the Pilbara region.
US-based drug maker Cosette has lost its bid to stay proceedings alleging it induced the treasurer to reject its $672 million tie-up with Mayne Pharma, with a judge finding Mayne has a right to prosecute its case and would be prejudiced by the delay.
A judge has refused to disqualify himself from case managing Mayne Pharma's latest dispute with US drug maker Cosette over the collapse of their $672 million merger agreement, calling the bid “plainly premature”.
Mayne Pharma has launched a bid for a $13.6 million gross sum costs order against US drug maker Cosette, after winning one of numerous legal challenges over the termination of a $672 million merger agreement.